Daily Market Report
Ventura
News Letter
| Summary | Date | Stock | Author | LTP | Target | Price at reco (Change since reco%) |
Upside(%) | Type | Report | Discuss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 21 Oct 2026 | Market Movement |
Ventura
|
Daily Note
|
||||||||
| 21 Oct 2026 | South Ind Bank |
BOB Capital Markets Ltd.
|
54.97 | 66.00 | 54.97 | 20.07 |
Buy
|
South Indian Bank (BUY): Consistent QoQ performance since last 3/4 quartersStrong liability management improved CoD/CoF, while …
BOB Capital Markets Ltd.
Strong liability management improved CoD/CoF, while a favourable mix shift and higher bond yields boosted YoA and NIMs
|
|||
| 21 Oct 2026 | World Economy and Markets |
Axis Direct
|
Daily Note
|
Daily Fundamental View:October 21, 2026
Axis Direct
Asian markets traded higher today, tracking gains in U.S. equity futures as strong earnings from major AI-related companies revived investor appetite for technology stocks. The Nikkei and Hang Seng advanced 1.61% and 0.28%, respectively, while Shanghai was nearly flat.
|
|||||||
| 21 Oct 2026 | Bajaj Housing Finance |
Deven Choksey
|
81.17 | 110.00 | 81.17 | 35.52 |
Buy
|
||||
| 21 Oct 2026 | Axis Bank |
Deven Choksey
|
1210.00 | 1507.00 | 1236.00 (-2.10%) | 24.55 |
Buy
|
Core margins hold; rate hikes set up a NIM recovery...
Deven Choksey
Axis Bank reported PAT of INR 7,003 Cr, up 37.6% YoY and down 1.6% QoQ, as a 23.8% QoQ fall in provisions offset an 11.3% QoQ rise in opex. NII grew 11.8% YoY and 5.0% QoQ to INR 15,371 Cr.
|
|||
| 21 Oct 2026 | ICICI Bank |
Deven Choksey
|
1385.00 | 1847.00 | 1381.00 (0.29%) | 33.36 |
Buy
|
||||
| 21 Oct 2026 | HDFC Bank |
Deven Choksey
|
706.95 | 981.00 | 712.00 (-0.71%) | 38.77 |
Buy
|
||||
| 21 Oct 2026 | Paras Healthcare |
Deven Choksey
|
693.00 |
IPO Subscribe
|
Improving Profitability and Expanding Regional Presence
Deven Choksey
Paras Healthcare operates eight tertiary and quaternary care hospitals under the Paras Health brand, with 2,211 beds across five states and one union territory. Occupancy rose to 61.75% in FY26 from 50.78% in FY25.
|
||||||
| 21 Oct 2026 | Bank Nifty |
SBI Securities
|
54976.90 |
Daily Note
|
|||||||
| 21 Oct 2026 | Nifty 50 |
SBI Securities
|
22811.35 |
Daily Note
|
|||||||
| 21 Oct 2026 | Jio Platforms |
invest4Edu
|
1119.00 |
IPO Subscribe
|
|||||||
| 21 Oct 2026 | Nifty 50 |
invest4Edu
|
22811.35 |
Daily Note
|
|||||||
| 21 Oct 2026 | Jio Platforms |
Deven Choksey
|
1119.00 |
IPO Subscribe
|
|||||||
| 20 Oct 2026 | UltraTech Cement |
ICICI Securities Limited
|
10849.00 | 11000.00 | 10650.00 (1.87%) | 1.39 |
Hold
|
Cost singe offsets volume surge; sector red flags warrant valuation calibration
ICICI Securities Limited
It is heartening to see UltraTech Cement (UTCEM)’s Q2FY27 volumes race 13% YoY (driving a 4% beat to our revenue forecast). Yet, high operating cost led to EBITDA being broadly in-line.
|
|||
| 20 Oct 2026 | Union Bank |
ICICI Securities Limited
|
182.00 | 230.00 | 180.70 (0.72%) | 26.37 |
Buy
|
||||
| 20 Oct 2026 | Tatva Chintan Pharma |
ICICI Securities Limited
|
1890.10 | 2385.00 | 1903.40 (-0.70%) | 26.18 |
Buy
|
||||
| 20 Oct 2026 | Rossari Biotech |
ICICI Securities Limited
|
416.90 | 520.00 | 437.50 (-4.71%) | 24.73 |
Buy
|
Efforts on rationalisation, price push, and efficiency driving margin improvement
ICICI Securities Limited
Rossari Biotech’s (Rossari) Q2FY27 EBITDA grew 20.9% YoY. While EBITDA margin also improved to 12.5%, it was constrained by elevated freight costs, volatility in raw material prices, and limited availability of Ethylene Oxide (EO).
|
|||
| 20 Oct 2026 | Piramal Finance |
ICICI Securities Limited
|
2019.00 | 2800.00 | 1948.70 (3.61%) | 38.68 |
Buy
|
||||
| 20 Oct 2026 | Just Dial |
ICICI Securities Limited
|
767.25 | 850.00 | 731.75 (4.85%) | 10.79 |
Buy
|
||||
| 20 Oct 2026 | Bajaj Finance |
ICICI Securities Limited
|
926.00 | 1250.00 | 957.35 (-3.27%) | 34.99 |
Buy
|
Strong H1FY27 growth momentum; AUM growth guidance raised to 26–27%
ICICI Securities Limited
Bajaj Finance (Bajaj)’s Q2FY27 and H1FY27 financial performance underscores its strong business franchise and robust portfolio health, enabling it to navigate macroeconomic headwinds, including elevated oil prices, El Niño concerns and a rising interest rate cycle.
|